EUVIMEDEUVIMED entdecken
Crossref

GPS2 confers l -asparaginase resistance in acute lymphoblastic leukemia cells through ATF4/ASNS axis

Jie Chen, Jili Luo, Yujie Liu, Jingjie Zhou, Hongjuan Cui iD, Longfei Deng iD

Carcinogenesis · 2025

DOI: 10.1093/carcin/bgaf035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Carcinogenesis, 2025. Verfasst von Jie Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Medical Research Institute, Southwest University, Chongqing 400715, China. Hauptthemen laut MEDLINE: Activating Transcription Factor 4, Drug Resistance, Neoplasm, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Asparaginase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

l-asparaginase (l-ASP) is an important chemotherapeutic agent used in the treatment of pediatric acute lymphoblastic leukemia (ALL). However, resistance to l-ASP is an unfavorable prognostic factor, and the mechanism underlying l-ASP resistance is not fully understood. Here, we show that activation of the activating transcription factor 4 (ATF4) and induced expression of downstream target asparagine synthetase (ASNS) play a pivotal role in l-ASP resistance of ALL cells. In addition, the G protein pathway suppressor 2 (GPS2) binds to ATF4 and stabilizes ATF4 protein. Mechanistically, GPS2 inhibits ubiquitin-proteasome degradation of ATF4 through impairing the interaction between ATF4 and beta-transducin repeat-containing E3 ubiquitin protein ligase (BTRC), an E3 ligase that triggers proteasomal degradation of ATF4. Moreover, GPS2 knockdown sensitizes ALL cells to l-ASP treatment via repressing the ATF4/ASNS axis in vitro and increases l-ASP efficacy against xenografted ALL tumors in vivo. Taken together, these findings demonstrate that GPS2 positively regulates the ATF4/ASNS axis to confer l-ASP resistance in ALL cells, suggesting a therapeutic potential of targeting this pathway to overcome l-ASP resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Activating Transcription Factor 4Drug Resistance, NeoplasmPrecursor Cell Lymphoblastic Leukemia-LymphomaAsparaginaseAspartate-Ammonia LigaseHumansAnimalsMiceXenograft Model Antitumor AssaysCell Line, Tumor

Stichwörter der Autor:innen

l-asparaginaseATF4GPS2acute lymphoblastic leukemiaresistance

Substanzen

Activating Transcription Factor 4AsparaginaseATF4 protein, humanAspartate-Ammonia Ligase

Autor:innen und Institutionen

  • Cancer Center, Medical Research Institute, Southwest University, Chongqing 400715, China.
  • Jinfeng Laboratory, Chongqing 401329, China.
  • Engineering Research Center for Cancer Biomedical and Translational Medicine, Southwest University, Chongqing 400715, China.
  • State Key Laboratory of Resource Insects, Southwest University, Chongqing 400715, China.

ORCID-Profile: Hongjuan Cui, Longfei Deng

Zitieren

APA

Chen, J., Luo, J., Liu, Y., Zhou, J., Cui, H., & Deng, L. (2025). GPS2 confers l -asparaginase resistance in acute lymphoblastic leukemia cells through ATF4/ASNS axis. Carcinogenesis. https://doi.org/10.1093/carcin/bgaf035

Vancouver

Chen J, Luo J, Liu Y, Zhou J, Cui H, Deng L. GPS2 confers l -asparaginase resistance in acute lymphoblastic leukemia cells through ATF4/ASNS axis. Carcinogenesis. 2025. doi:10.1093/carcin/bgaf035

BibTeX
@article{Chen2025,
  author = {Chen, Jie and Luo, Jili and Liu, Yujie and Zhou, Jingjie and Cui, Hongjuan and Deng, Longfei},
  title = {GPS2 confers l -asparaginase resistance in acute lymphoblastic leukemia cells through ATF4/ASNS axis},
  journal = {Carcinogenesis},
  year = {2025},
  doi = {10.1093/carcin/bgaf035}
}
Kostenlos starten →